key: cord-0771895-z8c63ns4
authors: Cao, Longxing; Goreshnik, Inna; Coventry, Brian; Case, James Brett; Miller, Lauren; Kozodoy, Lisa; Chen, Rita E.; Carter, Lauren; Walls, Lexi; Park, Young-Jun; Stewart, Lance; Diamond, Michael; Veesler, David; Baker, David
title: De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
date: 2020-08-03
journal: bioRxiv
DOI: 10.1101/2020.08.03.234914
sha: 9db75b19de9e888c988811a2368204dca8ebd608
doc_id: 771895
cord_uid: z8c63ns4

We used two approaches to design proteins with shape and chemical complementarity to the receptor binding domain (RBD) of SARS-CoV-2 Spike protein near the binding site for the human ACE2 receptor. Scaffolds were built around an ACE2 helix that interacts with the RBD, or de novo designed scaffolds were docked against the RBD to identify new binding modes. In both cases, designed sequences were optimized first in silico and then experimentally for target binding, folding and stability. Nine designs bound the RBD with affinities ranging from 100pM to 10nM, and blocked bona fide SARS-CoV-2 infection of Vero E6 cells with IC50 values ranging from 35 pM to 35 nM; the most potent of these — 56 and 64 residue hyperstable proteins made using the second approach — are roughly six times more potent on a per mass basis (IC50 ~ 0.23 ng/ml) than the best monoclonal antibodies reported thus far. Cryo-electron microscopy structures of the SARS-CoV-2 spike ectodomain trimer in complex with the two most potent minibinders show that the structures of the designs and their binding interactions with the RBD are nearly identical to the computational models, and that all three RBDs in a single Spike protein can be engaged simultaneously. These hyperstable minibinders provide promising starting points for new SARS-CoV-2 therapeutics, and illustrate the power of computational protein design for rapidly generating potential therapeutic candidates against pandemic threats.

maximize the density of inhibitory domains could have advantages over antibodies for direct 52 delivery into the respiratory system through intranasal administration, nebulization or dry powder 53 aerosol. We found previously that intranasal delivery of small proteins designed to bind tightly 54 to the influenza hemagglutinin can provide both prophylactic and therapeutic protection in 55 rodent models of lethal influenza infection (11). 56 57 We set out to design high-affinity protein minibinders to the COVID-19 Spike RBD that compete 58 with ACE2 binding. We explored two strategies: first we incorporated the alpha-helix from ACE2 59 which makes the majority of the interactions with the RBD into small designed proteins that 60 make additional interactions with the RBD to attain higher affinity (Fig 1A) . Second, we 61 designed binders completely from scratch without relying on known RBD-binding interactions 62 (Fig 1B) . An advantage of the second approach is that the range of possibilities for design is 63 much larger, and so potentially a greater diversity of high-affinity binding modes can be 64

identified. For the first approach, we used the Rosetta blueprint builder to generate miniproteins 65 which incorporate the ACE2 helix (human ACE2 residues 23 to 46 ). For the second approach, 66

we used RIF docking (12) and design using large miniprotein libraries (11) to generate binders 67 to distinct regions of the RBD surface surrounding the ACE2 binding site (Fig 1 and Fig S1) . 68 69

Large pools of designed minibinders (see Methods) made using the first and second 70 approaches, were encoded in long oligonucleotides and screened for binding to fluorescently 71 tagged RBD displayed on the surface of yeast cells. Deep sequencing identified three ACE2 72 helix scaffolded designs (Approach 1), and 105 de novo interface designs (Approach 2) that 73 were enriched following fluorescence activated cell sorting (FACS) for RBD binding. All three 74 ACE2-scaffolded designs and twelve of the de novo designs were expressed in E. coli and 75 purified. One of the ACE2-scaffolded designs expressed solubly and bound RBD with an affinity 76 of ~2 uM in biolayer interferometry (BLI) experiments (Fig S2) . Eleven of the twelve de novo 77 designs were soluble and bound RBD with affinities ranging from 100nM to 2uM (Fig S3) . 78 Affinity maturation of the ACE2-scaffolded design by PCR mutagenesis led to a variant, AHB1, 79 which bound RBD with an affinity of ~1 nM (Fig 3A) and blocked binding of ACE2 to the RBD 80 (Fig S4) , consistent with the design model. 81 82

For 50 minibinders made using Approach 2, we generated site saturation mutagenesis libraries 83 (SSMs) in which every residue in each design was substituted with each of the 20 amino acids 84 one at a time. Deep sequencing before and after FACS sorting for RBD binding revealed that 85 residues at the binding interface and protein core were largely conserved in 40 out of the 50 86 cases (Fig 2 and Fig S5) . For most of these minibinders, a small number of substitutions were 87 enriched in the FACS sorting; combinatorial libraries incorporating these substitutions were 88 constructed for the eight highest affinity designs and again screened for binding to the RBD at 89 concentrations down to 20pM. Each library converged on a small number of closely related 90 sequences; one of these was selected for each design (LCB1-LCB8) and found to bind the RBD 91 with high affinity on the yeast surface in a manner competed by ACE2 (Fig 3 and Fig S6) . 92 93 LCB1-LCB8 were expressed, purified from E. coli, and binding to the RBD assessed by BLI. 94

For six of the designs, the KD values ranged from 1-20 nM (Fig 3 and Fig S6) , and for two 95 (LCB1 and LCB3), the KD values were below 1 nM, which is too strong to measure reliably with 96 this technique (Fig 3) . On the surface of yeast cells, LCB1 and LCB3 showed binding signals at 97 5 pM of RBD following protease (trypsin and chymotrypsin) treatment (Fig S7) . Circular 98 dichroism spectra of the purified minibinders were consistent with the design models, and the 99 melting temperatures for most were greater than 90C (Figure 3 and FigS6). The designs 100 retained full binding activity after 14 days at room temperature (Fig S8) .

We characterized the structures of LCB1 and LCB3 in complex with the SARS-CoV-2 spike 103 ectodomain trimer at 2.7 Å and 3.1 Å resolution, respectively, revealing stoichiometric binding of 104 the minibinders to each RBD within the spike trimer (Fig 4 A-B , E-F and Fig S9, S11) . Although  105  the spike predominantly harbored two open RBDs for both complexes, we identified a subset of  106 particles with three RBDs open for the LCB3 complex (Fig 4 A-B , E-F and Fig S9, S11) . We 107 subsequently improved the resolvability of the RBD/LCB1 and RBD/LCB3 densities using 108 focused classification and local refinement yielding maps at 3.1 and 3.5 Å resolution enabling 109 visualization of the interactions formed by each minibinder with the RBD (Fig 4 C, G and Fig  110  S9-12) . 111 112 LCB1 and LCB3 dock with opposite orientations in the crevice formed by the RBD receptor-113 binding motif through extensive electrostatic interactions and shape complementarity mediated 114 by two out of the three minibinder ɑ-helices (Fig 4 C-D, G-H) . Similar to ACE2, the LCB1 and 115

LCB3 binding sites are buried in the closed S conformational state and require opening of at 116 least two RBDs to allow simultaneous recognition of the three binding sites (Fig 4 A-B , E-F). 117

Both LCB1 and LCB3 form numerous hydrogen bonds and salt bridges with the receptor-118 binding motif resulting in the burial of a surface area of ~1,000Å^2 and ~800Å^2, respectively 119 (Fig S10 and Fig S12) . The extensive networks of polar and hydrophobic interactions explain 120 the subnanomolar affinities of these inhibitors. As designed, the binding sites for LCB1 and 121

LCB3 overlap with that of ACE2, and hence should compete for binding to the RBD and inhibit 122 viral attachment at the host cell surface. 123 124

Superimposition of the designed LCB1/RBD or LCB3/RBD models to the corresponding cryoEM 125

structures, using the RBD as reference, show that the binding poses closely match the design 126 with backbone Cɑ rmsd of 1.27 Å and 1.9Å for LCB1 and LCB3, respectively (Fig. 4D , H) and 127 most of the polar interactions in the design models match nicely with the CryoEM structure ( Fig  128  S10 , S12). These data show that the computational design method can have quite high 129

accuracy. The structure comparisons in Fig. 4D and 4H are to the original design models; the 130 substitutions that increased binding affinity are quite subtle and have very little effect on 131 backbone geometry. 132 133 We investigated the capacity of AHB1 and LCB1-5 to prevent infection of human cells by bona 134

fide SARS-CoV-2. Varying concentrations of minibinders were incubated with 100 focus-forming 135 units (FFU) of SARS-CoV-2 and then added to Vero E6 monolayers. AHB1 strongly neutralized 136 SARS-CoV-2 (IC50 of 35nM), whereas a control influenza minibinder showed no neutralization 137 activity (Fig 5A) . Next, we tested the Approach 2 designed minibinders LCB1-5. We observed 138 even more potent neutralization of SARS-CoV-2 by LCB1 and LCB3 with IC50 values of 34.46pM 139 and 48.1pM, respectively (Fig 5B) . On a molar basis, these values are approximately 6-fold 140 lower than the most potent anti-SARS-CoV-2 monoclonal antibody described to date (13); on a 141 mass basis, because of their very small size, the designs are more potent than any of these 142

antibodies. 143 144

The minibinders designed in this work have potential advantages over antibodies as potential 145

therapeutics. Together, they span a range of binding modes, and in combination viral mutational 146 escape would be quite unlikely (Fig S1) . The retention of activity after extended time at elevated 147 temperatures suggests they might not require a cold chain. The designs are 20-fold smaller than 148 a full antibody molecule, and hence in an equal mass have 20-fold more potential neutralizing 149 sites, increasing the potential efficacy of a locally administered drug. The cost of goods and the 150 ability to scale to very high production should be lower for the much simpler miniproteins, which 151 unlike antibodies, do not require expression in mammalian cells for proper folding. The small 152 size and high stability should also make them amenable to formulation in a gel for nasal 153 application, and to direct delivery into the respiratory system by nebulization or as a dry powder. 154 We will be exploring alternative routes of delivery in the months ahead as we seek to translate 155 the high potency neutralizing proteins into SARS-Cov2 therapeutics and prophylactics. 156

Immunogenicity is a potential problem with any foreign molecule, but for previously 157 characterized small de novo designed proteins little or no immune response has been observed 158 (11, 14) , perhaps because the high solubility and stability together with the small size makes 159 presentation on dendritic cells less likely. 160 161

Timing is critical in a pandemic outbreak: potent therapeutics are needed in as short a time as 162 possible. We began to design minibinders in January 2020 based on a Rosetta model of the 163 SARS-CoV-2 Spike structure and switched to the crystal structures once they became available. 164

By the end of May 2020, we had identified very potent neutralizers of infectious virus; during 165 this same time, a number of neutralizing monoclonal antibodies were identified. We believe that 166 with continued development, the computational design approach can become much faster. First, 167

as structure prediction methods continue to increase in accuracy, target models suitable for 168 design could be generated within a day of determining the genome sequence of a new 169

pathogen. Second, with continued improvement in computational design methods, it should be 170 possible to streamline the workflow described here, which required screening of large sets of 171 computational designs, followed by experimental optimization, to identify very high affinity 172

binders. The very close agreement of the cryoEM structures of LCB1 and LCB2 with the 173 computational design models suggest that the main challenges to overcome are not in the de 174 novo design of proteins with shape and chemical complementarity to the target surface, but in 175 recognizing the best candidates and identifying a small number of affinity increasing 176

substitutions. The large amount of data collected in protein interface design experiments such 177 as those described here should inform the improvement of the detailed atomic models at the 178 core of Rosetta design calculations, as well as complementary machine learning approaches, 179

to enable recognition and improved sequence design of the best candidates; this would enable 180 the rapid in silico design of pM inhibitors like LCB1 and LCB3. With continued methods 181 development, we believe that it will become possible to generate ultra-high-affinity, pathogen 182 neutralizing designs within weeks of obtaining genome sequence. Preparing against unknown 183 future pandemics is difficult, and such a capability could be an important component of a 184

general response strategy. Designing miniprotein binders based on the ACE2 helix 208 209

The crystal structure (PDB: 6M0J) of the RBD bound to ACE2 (4) was refined with the Rosetta 210

FastRelax protocol with coordinate constraints, and the main binding helix of ACE2 (residue 23 -211 46) was extracted and used as the starting point for miniprotein generation. Miniprotein binder 212 generation began by defining a variety of 3-helical bundles using the RosettaRemodel blueprint 213

(15)} format with the requirement that the ACE2 helix was incorporated into one of the helices. 214

1,974 blueprints that differed in the lengths of the helices and the loop types were generated. 215

The blueprints were used to generate backbones using the Rosetta Monte Carlo-based 216 fragment assembly protocol (16), while keeping the ACE2 helix fixed. Specially, the RBD 217 structure was loaded into a hashing grid for fast clash checking to guarantee the newly 218 generated backbones are not clashing with the RBD. The generated miniprotein was subjected 219

to a 3-stage sequence design protocol. Firstly, only interface residues on the miniproteins were 220 designed using the PackRotamersMover to quickly select designs that could make extra 221

contacts with RBD basides of the ACE2 helix. The whole miniprotein except the key interacting 222 residues on the ACE2 helix were then designed using the FastDesign protocol, activating 223 between side-chain rotamer optimization and gradient-descent-based energy minimization. 224

Lastly, the interface residues were further optimized with another round of FastDesign to 225 improve shape and chemically complementary. The monomeric metrics and the interface 226 metrics were calculated using Rosetta. Top 5,000 designs were selected based on the protein 227 folding metrics (score_pre_res, buried non-polar area, local structure and sequence agreement) 228

and interface metrics (ddg, shape complementarity, interface buried solvent accessible area). 229

Both the quality of the designed monomeric structure and the accuracy of designed interface 230

interactions are important for successfully making miniprotein binders, which is hard to achieve 231 through one Monte Carlo fragment assembly trajectory. Thus, we performed a second-round 232 design based on the above generated design models. In detail, 273 helix hairpins that make 233 good contacts with the RBD are selected based on the above-mentioned interface metrics. 234

Starting from these helix hairpins, the third helix was built using the same fragment assembly 235 protocol. Sequence design was performed on the generated backbone, except the first stage 236

sequence design was omitted. The outputs were filtered by protein folding metrics and interface 237 binding metrics, and 18,000 designs were selected. 238 239

De novo binder design 240 241

The crystal structure (PDB: 6M0J) of the RBD bound to ACE2 (4) was refined with the Rosetta 242

FastRelax protocol with coordinate constraints, and the RBD subunit was extracted for 243 subsequent steps. Initial docking conformations were generated by RifDock (12). Briefly, billions 244 of individual disembodied amino acids were docked against the ACE2 binding region on RBD 245

using RifDock. The ones that passed a specific energy cutoff value (-1.5 Rosettta energy unit) 246

were stored and the corresponding inverse rotamers were generated. The de novo scaffold 247 library (11) of 19,000 mini-proteins (in length 56 -65 residues) were docked into the field of the 248 inverse rotamers to produce initial docked conformations. These docked conformations were 249 further optimized using the FastDesign protocol to generate shape and chemically 250 complementary interfaces. Computational metrics of the final design models were calculated 251

using Rosetta, which includes ddg, shape complementary and interface buried solvent 252 accessible surface area. Top 100,000 designs based on the above metrics were selected and 253

an Agilent DNA library were ordered for DNA synthesis. 254

All protein sequences were padded to a uniform length (88 aa for approach 1 and 65 for 256 approach 2) by adding a (GGGS)n linker at the C terminal of the designs, to avoid the biased 257 amplification of short DNA fragments during PCR reactions. The protein sequences were 258 reversed translated and optimized using DNAworks2.0 (17) with the S. cerevisiae codon 259 frequency novo designs, the library was sorted twice using the with-avidity method at 1 uM RBD, followed 295 by several without-avidity sort in the third round of sorting with RBD concentrations at 1uM, 296

100nM and 10 nM. The SSM library was screened using the without-avidity method for four 297 rounds, with RBD concentrations at 1uM, 100nm, 10nM and 1nM. The error-prone library and 298 the combinatorial libraries were sorted to convergence by decreasing the target concentration 299

with each subsequent sort and collecting only the top 0.1% of the binding population. The final 300 sorting pool of the error-prone library was sequenced using Illumina MiSeq kit to identify all 301 beneficial mutations. The final sorting pools of the combinatorial libraries were plated on C-trp-302 ura plates and the sequences of individual clones were determined by Sanger sequencing. 303

For protease treatment, the cells were firstly washed with TBS (20 mM Tris 100 mM NaCl pH 304 8.0). Protolysis was initiated by adding 250 µL of room temperature TBS with 1 uM of trypsin 305 and 0.5 uM of chymotrypsin, followed by vortexing and incubating the reaction at room 306 temperature for 5 min. The reaction was quenched by adding 1 mL of chilled PBSF, and cells 307

were immediately washed 4x in chilled PBSF. The cells were then labeled with RBD using the 308 above mentioned protocol. 309

Genes encoding the designed protein sequences were synthesized and cloned into modified 311

pET HEPES (pH 7.4) , 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20, 0.5% non-345 fat dry milk) for 360 s. Analyte proteins were diluted from concentrated stocks into binding 346

buffer. After baseline measurement in the binding buffer alone, the binding kinetics were 347 monitored by dipping the biosensors in wells containing the target protein at the indicated 348 concentration (association step) and then dipping the sensors back into baseline/buffer 349 (dissociation). For the ACE2 competition assay, ACE2-Fc protein (house made) was loaded 350 onto proteinA biosensors (SA ForteBio) at 20 nM in binding buffer for 360 s, and the RBD 351 protein (house made) was used as the ligand with a concentration of 100 nM. AHB1 protein was 352 diluted into the ligand well at the indicated concentrations. Same Octet protocol as above 353 mentioned was applied for acquiring the association and dissociation spectrums. foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an 368

ImmunoSpot microanalyzer (Cellular Technologies). Data was processed using Prism software 369 (GraphPad Prism 8.0). 370 371

Cryo Electron microscopy 372 373

To prepare SARS-CoV-2 S/LCB complexes, 10-fold molar excesses of LCB1 or LCB3 were 374 incubated with SARS-CoV-2 HexaPro Spike protein (18) for 1 h on ice, and the complexes were 375 purified on a Superose 6 Increase 10/300 GL column. 3 μL of 1 mg/ml purified SARS-CoV 376 S/LCB complexes were loaded onto a freshly glow-discharged (30 s at 20 mA) 1.2/1.3 377

UltrAuFoil grid (300 mesh) prior to plunge freezing using a vitrobot Mark IV (ThermoFisher 378 Scientific) using a blot force of 0 and 5.5 second blot time at 100% humidity and 25°C. Data 379

were acquired using an FEI Titan Krios transmission electron microscope operated at 300 kV 380

and equipped with a Gatan K2 Summit direct detector and Gatan Quantum GIF energy filter, 381 operated in zero-loss mode with a slit width of 20 eV. Automated data collection was carried out 382

using Leginon at a nominal magnification of 130,000x with a pixel size of 0.525 Å. The dose rate 383 was adjusted to 8 counts/pixel/s, and each movie was acquired in super-resolution mode 384 fractionated in 50 frames of 200 ms. 2,500 micrographs were collected with a defocus range 385 between -0.5 and -2.5 μm. Movie frame alignment, estimation of the microscope contrast-386 transfer function parameters, particle picking, and extraction were carried out using Warp. 387

Particle images were extracted with a box size of 800 binned to 400 yielding a pixel size of 1.05 388 Å. Reference-free 2D classification was performed using CryoSPARC to select well-defined 389 particle images. These selected particles were subjected to 3D classification in Relion. 3D 390 refinements were carried out using non-uniform refinement along with per-particle defocus 391 refinement in CryoSPARC. Selected particle images were subjected to the Bayesian polishing 392 procedure implemented in Relion3.0. After determining a refined 3D structure, the particles were 393 then subjected to focus 3D classification without refining angles and shifts using a soft mask on 394

Receptor binding motif (RBM) and LCB region with a tau value of 60. articles belonging to 395 classes with the best resolved LCB1/3 density were selected and subject to local refinement 396

with CryoSPARC, resulting in 3D reconstructions with improved quality for the minibinders. 397

Local resolution estimation, filtering, and sharpening were carried out using CryoSPARC. 398

Reported biolayer interferometry experiments. Fc-tagged RBD protein was loaded onto Protein A 532 biosensors, and allowed to equilibrate before setting the baseline to zero at t=0. The BLI tips 533

were then placed into different concentrations of AHB1 as indicated for 600 seconds. The tips 534

were then placed into buffer solution and the dissociation was monitored for an additional 1,000 535 seconds. Exclusion chromatography profiles of the E. coli expressed initial hits by the de novo approach. 557 (B) Binding profiles of de novo miniproteins to RBD in the biolayer interferometry experiments. 558

The biotinylated RBD protein was loaded onto the Streptavidin (SA) biosensors and allowed to 559 equilibrate before setting the baseline to zero at t=0. The BLI tips were then placed into different 560 concentrations of candidate minibinders (1 uM) as indicated for 150-200 seconds. The tips were 561 then placed into buffer solution and the dissociation was monitored for an additional 600 562 seconds .  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577   578  579  580  581  582  583  584  585 586 Figure S4 | The ACE2 scaffolded helix design AHB1 blocks binding of ACE2 to the RBD. 587

The Fc-tagged ACE2 protein was loaded onto the Protein A biosensors in the BLI assay, and 588 allowed to equilibrate before setting the baseline to zero at t=0. The BLI tips were then then 589 placed for 100 seconds into different concentrations of AHB 1 minibinder as indicated, together 590 with a constant concentration of 100 nM of RBD. The tips were then placed into buffer solution 591 and the dissociation was monitored for an additional 150 seconds. 

SA) biosensors and allowed to equilibrate before 613 setting the baseline to zero at t=0. The BLI tips were then placed into different concentrations of 614 candidate minibinders (at concentrations noted) as indicated for 120 or 600 seconds. The tips 615 were then placed into buffer solution and the dissociation was monitored for an additional 300 or 616 1,000 seconds. C. Circular dichroism (CD) spectra at different temperatures, and D

Figure S7 | LCB1 and LCB3 bind to RBD at 5 pM following protease treatment. Yeast cells 662 displaying LCB1 and LCB3 were incubated with 1uM trypsin and 0.5 uM chymotrypsin, washed, 663 incubated with 5 pM biotinylated RBD, and analyzed by flow cytometry

LCB1 and 689 LCB3 were left on the lab bench at room temperature for 14 days and the binding with RBD was 690 checked using the BLI assay. Fc-tagged RBD protein was loaded onto Protein A biosensors, 691 and allowed to equilibrate before setting the baseline to zero at t=0. The BLI tips were then 692 placed into different concentrations LCB1 and LCB3 as indicated for 2500 seconds. The tips 693 were then placed into buffer

Representative electron micrograph (A) and 2D class averages (B) 701 of SARS-CoV-2 S in complex with LCB1 embedded in vitreous ice. Scale bar: 400Å. C. Gold-702 standard Fourier shell correlation curves for the LCB1-bound trimer (black solid line) and locally 703 refined RBD/LCB1 (grey solid line)

Local resolution maps calculated using cryoSPARC for LCB1/S (D) and the locally refined 705

F. Zoomed-in view of the interface between LCB1 (magenta) and the 706 SARS-CoV-2 RBD (cyan) with the corresponding region of density shown as blue mesh

The computational model (silver grey) of LCB1/RBD complex is overlaid with 714 its CryoEM structure (cyan for RBD and pink for LCB1)

Representative electron micrograph (A) and 2D class averages (B) 724 of SARS-CoV-2 S in complex with LCB3 embedded in vitreous ice. Scale bar: 400Å. C. Gold-725 standard Fourier shell correlation curves for the LCB3-bound trimer (black solid line) and locally 726 refined RBD/LCB3 (grey solid line)

Local resolution maps calculated using cryoSPARC for LCB3/S (D) and the locally refined 728

RBD/LCB3 region (E). F. CryoEM reconstruction of LCB3 in complex with SARS-CoV-2 S with 729 three RBDs open. G. Zoomed-in view of the interface between LCB3 (salmon) and the

RBD (cyan) with the corresponding region of density shown as blue mesh

The computational model (silver grey) of LCB3/RBD complex is overlaid 736 with its CryoEM structure (cyan for RBD and light pink for LCB3)

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in 742 the Respiratory Tract

A human neutralizing antibody targets the receptor binding site of SARS-744 CoV-2

Structural and functional analysis of a potent sarbecovirus neutralizing 746 antibody. bioRxiv

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 748 ACE2 receptor

A highly conserved cryptic epitope in the receptor binding domains of 750 SARS-CoV-2 and SARS-CoV

A noncompeting pair of human neutralizing antibodies block COVID-19 752 virus binding to its receptor ACE2

Antibody-dependent enhancement of influenza disease promoted 754 by increase in hemagglutinin stem flexibility and virus fusion kinetics

Fc receptors in antibody-dependent enhancement of viral infections

Rapid COVID-19 vaccine development

Structure, function and antigenicity of the SARS-CoV-2 spike 760 glycoprotein. bioRxiv

Massively parallel de novo protein design for targeted therapeutics

De novo design of a fluorescence-activating beta-barrel

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-766 2 Infection

De novo design of potent and selective mimics of IL-2 and IL-15. 768

RosettaRemodel: a generalized framework for flexible backbone 770 protein design

Principles for designing ideal protein structures

DNAWorks: an automated method for designing 774 oligonucleotides for PCR-based gene synthesis

Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes